Home

Download

Statistics

Examples

Help

Contact

	Fusion Gene Summary
	Fusion Gene ORF analysis
	Fusion Genomic Features
	Fusion Protein Features
	Fusion Gene Sequence
	Fusion Gene PPI analysis
	Related Drugs
	Related Diseases

Fusion gene:SBF2-IPO7 (FusionGDB2 ID:78816)

Fusion Gene Summary for SBF2-IPO7

Fusion gene summary

Fusion gene information	Fusion gene name: SBF2-IPO7
	Fusion gene ID: 78816
		Hgene	Tgene
	Gene symbol	SBF2	IPO7
	Gene ID	81846	10527
	Gene name	SET binding factor 2	importin 7
	Synonyms	CMT4B2\|DENND7B\|MTMR13	Imp7\|RANBP7
	Cytomap	11p15.4	11p15.4
	Type of gene	protein-coding	protein-coding
	Description	myotubularin-related protein 13DENN/MADD domain containing 7Binactive phosphatidylinositol 3-phosphatase 13	importin-7RAN-binding protein 7
	Modification date	20200328	20200313
	UniProtAcc	.	O95373
	Ensembl transtripts involved in fusion gene	ENST00000256190, ENST00000527019,	ENST00000379719, ENST00000533680,
Fusion gene scores	* DoF score	27 X 17 X 10=4590	7 X 7 X 3=147
	# samples	30	7
	** MAII score	log2(30/4590*10)=-3.93545974780529 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0	log2(7/147*10)=-1.0703893278914 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0
Context	PubMed: SBF2 [Title/Abstract] AND IPO7 [Title/Abstract] AND fusion [Title/Abstract]
Most frequent breakpoint	SBF2(10215449)-IPO7(9424837), # samples:1
Anticipated loss of major functional domain due to fusion event.

* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez

Partner

Gene

GO ID

GO term

PubMed ID

Fusion gene breakpoints across SBF2 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Fusion gene breakpoints across IPO7 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Fusion gene information from two resources (ChiTars 5.0 and ChimerDB 4.0)
* All genome coordinats were lifted-over on hg19.
* Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser.

Source	Disease	Sample	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand
ChimerDB4	STAD	TCGA-BR-8077-01A	SBF2	chr11	10215449	-	IPO7	chr11	9424837	+

Top

Fusion Gene ORF analysis for SBF2-IPO7

Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure.
* Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser.

ORF	Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand
In-frame	ENST00000256190	ENST00000379719	SBF2	chr11	10215449	-	IPO7	chr11	9424837	+
5CDS-3UTR	ENST00000256190	ENST00000533680	SBF2	chr11	10215449	-	IPO7	chr11	9424837	+
intron-3CDS	ENST00000527019	ENST00000379719	SBF2	chr11	10215449	-	IPO7	chr11	9424837	+
intron-3UTR	ENST00000527019	ENST00000533680	SBF2	chr11	10215449	-	IPO7	chr11	9424837	+

ORFfinder result based on the fusion transcript sequence of in-frame fusion genes.

Henst

Tenst

Hgene

Hchr

Hbp

Hstrand

Tgene

Tchr

Tbp

Tstrand

Seq length
(transcript)

BP loci
(transcript)

Predicted start
(transcript)

Predicted stop
(transcript)

Seq length
(amino acids)

ENST00000256190

SBF2

chr11

10215449

ENST00000379719

IPO7

chr11

9424837

6244

279

3311

1098

DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	No-coding score	Coding score
ENST00000256190	ENST00000379719	SBF2	chr11	10215449	-	IPO7	chr11	9424837	+	5.30E-05	0.99994695

Top

Fusion Genomic Features for SBF2-IPO7

FusionAI prediction of the potential fusion gene breakpoint based on the pre-mature RNA sequence context (+/- 5kb of individual partner genes, total 20kb length sequence). FusionAI is a fusion gene breakpoint classifier based on convolutional neural network by comparing the fusion positive and negative sequence context of ~ 20K fusion gene data. From here, we can have the relative potentency of the 20K genomic sequence how individual sequnce will be likely used as the gene fusion breakpoints.

Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	1-p	p (fusion gene breakpoint)
SBF2	chr11	10215448	-	IPO7	chr11	9424836	+	3.28E-06	0.99999666
SBF2	chr11	10215448	-	IPO7	chr11	9424836	+	3.28E-06	0.99999666

Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions. We integrated a total of 44 different types of human genomic feature loci information across five big categories including virus integration sites, repeats, structural variants, chromatin states, and gene expression regulation. More details are in help page.

Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions that are ovelapped with the top 1% feature importance score regions. More details are in help page.

Top

Fusion Protein Features for SBF2-IPO7

Go to
FGviewer for the breakpoints of chr11:10215449-chr11:9424837
.
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.

Main function of each fusion partner protein. (from UniProt)

Hgene	Tgene
.	IPO7 O95373
FUNCTION: Might normally function as a transcriptional repressor. EWS-fusion-proteins (EFPS) may play a role in the tumorigenic process. They may disturb gene expression by mimicking, or interfering with the normal function of CTD-POLII within the transcription initiation complex. They may also contribute to an aberrant activation of the fusion protein target genes.	FUNCTION: Functions in nuclear protein import, either by acting as autonomous nuclear transport receptor or as an adapter-like protein in association with the importin-beta subunit KPNB1. Acting autonomously, is thought to serve itself as receptor for nuclear localization signals (NLS) and to promote translocation of import substrates through the nuclear pore complex (NPC) by an energy requiring, Ran-dependent mechanism. At the nucleoplasmic side of the NPC, Ran binds to importin, the importin/substrate complex dissociates and importin is re-exported from the nucleus to the cytoplasm where GTP hydrolysis releases Ran. The directionality of nuclear import is thought to be conferred by an asymmetric distribution of the GTP- and GDP-bound forms of Ran between the cytoplasm and nucleus. Mediates autonomously the nuclear import of ribosomal proteins RPL23A, RPS7 and RPL5. Binds to a beta-like import receptor binding (BIB) domain of RPL23A. In association with KPNB1 mediates the nuclear import of H1 histone and the Ran-binding site of IPO7 is not required but synergizes with that of KPNB1 in importin/substrate complex dissociation. In vitro, mediates nuclear import of H2A, H2B, H3 and H4 histones. {ECO:0000269\|PubMed:10228156, ECO:0000269\|PubMed:9687515}.; FUNCTION: (Microbial infection) Mediates the nuclear import of HIV-1 reverse transcription complex (RTC) integrase. Binds and mediates the nuclear import of HIV-1 Rev. {ECO:0000269\|PubMed:12853482, ECO:0000269\|PubMed:16704975}.

Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at
download page

* Minus value of BPloci means that the break pointn is located before the CDS.

- In-frame and retained protein feature among the 13 regional features.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Protein feature

Protein feature note

Tgene

IPO7

chr11:10215449

chr11:9424837

ENST00000379719

885_957

28.0

1039.0

Compositional bias

Note=Asp-rich

- In-frame and not-retained protein feature among the 13 regional features.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Protein feature

Protein feature note

Hgene

SBF2

chr11:10215449

chr11:9424837

ENST00000256190

1108_1584

47.0

1850.0

Domain

Myotubularin phosphatase

Hgene

SBF2

chr11:10215449

chr11:9424837

ENST00000256190

1743_1847

47.0

1850.0

Domain

Hgene

SBF2

chr11:10215449

chr11:9424837

ENST00000256190

191_324

47.0

1850.0

Domain

cDENN

Hgene

SBF2

chr11:10215449

chr11:9424837

ENST00000256190

326_427

47.0

1850.0

Domain

dDENN

Hgene

SBF2

chr11:10215449

chr11:9424837

ENST00000256190

7_172

47.0

1850.0

Domain

uDENN

Hgene

SBF2

chr11:10215449

chr11:9424837

ENST00000256190

871_957

47.0

1850.0

Domain

GRAM

Tgene

IPO7

chr11:10215449

chr11:9424837

ENST00000379719

22_101

28.0

1039.0

Domain

Importin N-terminal

Top

Fusion Gene Sequence for SBF2-IPO7

For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. To have fusion amino acid sequence, we ran ORFfinder and chose the longest ORF among the all predicted ones.

>In-frame_ENST00000256190_ENST00000379719_TCGA-BR-8077-01A_SBF2_chr11_10215449_-_IPO7_chr11_9424837_length(transcript)=6244nt_BP=279nt
GGTTGTCAAACATGGCTGAAGCGCTGCCGCTGCCGCTACTGCCGCTGCAGGGAAAATGCTGAGCCCTCCCGGGCCGGGTGGGCGGCGGCG
GCGAGGGCGGCGACGGGGACCCGCTTCCCGAGCGCGGCGGCGGCGGCCATGGCCCGGCTGGCTGACTACTTCATCGTGGTAGGCTATGAC
CACGAGAAGCCAGGATCAGGAGAAGGTCTGGGGAAAATAATCCAGAGATTTCCACAGAAGGACTGGGATGATACACCTTTTCCACAGGGA
ATTGAGTTGGCACACAAGTCTCTGAATTTTGTCTCAACACTGCTCCAGATTACTATGTCGGAACAGCTGGATTTACCTGTGAGACAGGCA
GGTGTTATCTATCTGAAAAATATGATAACACAGTATTGGCCTGATCGAGAAACAGCACCAGGGGATATATCCCCTTATACTATTCCAGAA
GAAGATCGCCATTGTATTCGAGAAAATATTGTAGAAGCCATTATCCATTCTCCTGAGCTCATCAGGGTACAGCTTACTACATGCATTCAT
CACATCATCAAACATGATTATCCAAGCCGCTGGACTGCCATTGTGGACAAAATTGGCTTTTATCTTCAGTCCGATAACAGTGCTTGTTGG
CTAGGAATTCTTCTTTGCCTTTATCAGCTTGTGAAAAATTATGAGTATAAAAAACCAGAGGAGCGGAGTCCATTGGTAGCAGCAATGCAG
CATTTTCTGCCAGTTCTAAAGGATCGTTTTATCCAGCTTCTTTCTGACCAGTCTGATCAGTCTGTCCTCATCCAGAAACAGATATTCAAG
ATCTTCTATGCTCTTGTTCAGTATACACTACCACTGGAACTGATAAACCAACAGAACCTGACAGAATGGATAGAAATTTTAAAGACTGTT
GTGAACAGGGATGTACCTAATGAAACACTTCAAGTTGAAGAAGATGATCGACCTGAGTTACCATGGTGGAAATGCAAGAAGTGGGCCTTA
CATATTTTAGCAAGACTTTTTGAAAGATATGGAAGCCCTGGCAATGTTTCCAAGGAGTATAATGAATTTGCTGAAGTATTTCTGAAGGCA
TTTGCTGTTGGTGTCCAGCAAGTTTTATTGAAGGTGTTATATCAGTACAAGGAGAAGCAATATATGGCTCCTCGAGTTTTACAACAGACA
TTAAATTATATTAATCAAGGAGTTTCTCATGCTCTCACCTGGAAGAATCTGAAGCCCCATATACAAGGCATTATCCAAGATGTTATTTTT
CCATTGATGTGCTATACAGATGCTGATGAGGAACTTTGGCAAGAAGACCCTTACGAATATATACGCATGAAGTTTGATGTGTTTGAAGAT
TTCATTTCTCCTACCACTGCTGCCCAGACACTTTTGTTTACAGCCTGTAGTAAGAGGAAAGAGGTACTGCAAAAGACTATGGGATTTTGT
TACCAGATTCTTACAGAACCAAATGCTGACCCTCGAAAAAAAGATGGAGCCCTGCATATGATTGGCTCTTTAGCTGAAATACTTCTGAAG
AAAAAGATCTATAAAGATCAGATGGAATACATGTTGCAGAATCATGTATTCCCTCTCTTCAGCAGTGAACTAGGCTACATGAGAGCAAGG
GCTTGCTGGGTACTTCACTATTTTTGTGAAGTGAAGTTCAAAAGTGATCAGAACCTTCAAACAGCCTTAGAGCTAACAAGAAGATGTCTG
ATTGATGATAGAGAAATGCCTGTGAAAGTGGAAGCTGCCATTGCCCTTCAAGTATTGATCAGCAATCAAGAAAAAGCTAAAGAATATATC
ACACCATTCATCAGACCTGTAATGCAGGCTCTTCTTCACATTATAAGAGAAACAGAAAATGATGACCTTACCAATGTAATTCAGAAAATG
ATCTGTGAATATAGTGAAGAAGTTACTCCTATTGCAGTAGAAATGACACAACATTTGGCAATGACATTTAACCAAGTAATCCAGACGGGG
CCAGATGAAGAAGGTAGTGATGACAAAGCAGTTACTGCTATGGGAATTCTGAATACAATTGATACACTTCTTAGTGTAGTTGAAGATCAT
AAAGAGATAACCCAACAGCTTGAGGGAATCTGCTTACAGGTCATTGGTACTGTTTTACAACAGCATGTCTTAGAATTCTATGAGGAGATC
TTCTCTTTAGCGCACAGTTTGACATGTCAACAAGTGTCTCCACAGATGTGGCAGCTACTACCCCTTGTATTTGAAGTCTTTCAGCAAGAT
GGCTTTGATTACTTTACAGATATGATGCCCCTCCTTCATAATTATGTAACAGTTGATACAGACACACTTCTGTCTGACACCAAGTATCTT
GAAATGATATACAGTATGTGCAAAAAGGTTCTTACAGGAGTTGCAGGAGAAGATGCAGAGTGTCATGCAGCAAAATTGTTAGAGGTCATC
ATTCTGCAGTGCAAAGGGCGTGGCATTGACCAGTGCATTCCCTTATTCGTGGAAGCAGCCTTAGAAAGACTGACAAGAGAGGTTAAGACA
AGTGAACTTCGAACTATGTGTCTGCAAGTTGCAATTGCAGCTTTGTATTATAATCCACACCTACTACTCAATACCTTAGAAAATCTTCGC
TTCCCTAATAATGTTGAACCAGTTACAAATCATTTTATTACACAGTGGCTTAATGATGTTGACTGTTTCTTGGGGCTTCATGACAGAAAG
ATGTGTGTTCTCGGACTCTGTGCTCTTATTGATATGGAACAGATACCCCAAGTTTTAAATCAGGTTTCTGGACAGATTTTGCCGGCTTTT
ATCCTTTTATTTAACGGATTGAAAAGAGCATATGCCTGCCATGCAGAACATGAGAATGACAGTGATGATGATGATGAAGCTGAAGATGAT
GATGAAACCGAGGAACTGGGGAGTGATGAAGATGATATTGATGAAGATGGGCAAGAATATTTGGAGATTCTGGCTAAGCAGGCTGGTGAA
GATGGAGATGATGAAGATTGGGAAGAAGATGATGCTGAAGAGACTGCTCTGGAAGGCTATTCCACAATCATTGATGATGAAGATAACCCT
GTTGATGAGTATCAGATATTTAAAGCTATCTTTCAAACTATTCAAAATCGTAATCCTGTGTGGTATCAGGCACTGACTCACGGTCTTAAT
GAAGAACAAAGAAAACAGTTACAGGACATAGCAACTCTGGCTGATCAAAGAAGAGCAGCCCATGAATCCAAAATGATTGAGAAGCATGGA
GGATACAAATTCAGTGCTCCAGTTGTGCCAAGTTCTTTCAATTTTGGAGGCCCAGCACCAGGGATGAATTGAGTTATCTCTTTCTTTCCT
GCTGTGTGCTTGTAGTGAAGAGCTTGTGTTCCTCCTAGTAGTGGTTCCAGAACTGGTTCATGTTATCTATTCTAAACTAATAATCAATAG
ATGGACAAAAGAAACAACAACCCCAGGAGATGGGACCTGATCATGCAACCTGGCACTGGAAAAGAAATCAGCGGGATTTTGGGGGTGGGG
GGGGATGGGAGGTACCTTAGAGGGAGTATTTTCTTTATTTTTTGAAGAAAGTAAGATCCTGACTCTGAAGCTTCAAAGTGACACTGTGGA
AATCTGAAACGAGGGGATGTCATGAAGGCAGCTTTTCTTTTTCTGAGGAAAAAATAGGCATGGGCTACAGGACTATTTAAAATGTCTCAT
TTACAGTATAAAACTCAAAGGTAGATGTAATTTTTACACCTATGAGTATTTGTCCAATTTCTGTCTCTTCCTCACCATTGGGTATCTATT
CTTTATATGTAAATAAGATAAGGTCATCTGATAGCCTTATTCAGTCTTCATCATTTTCATCATTGTTCCTATGTAGATTATTGGACATTT
ATTGTAGCACTACATAACTGATTATAAAAATCTGTAAATGAATTAGCACTTTCATATTGAAACAAGCCTGCTAGCCTATGTATAAAATAG
CAAAATGTTTGCTGTTTATAAAAAGATGTAATGGGGTGGGGGGCAGGGGTAATTTCAAGTTATTAATTTAAAAATGAACTAGCAATTTTG
TACCTGGTGACTTTGTGGTGCACTCACCTCTGATAGTGACTTGAATTCGGTATGTAAAAAGGGGTTAGTGGTATTTCATTGCTGCTAAAA
ATGACAACTCCCTCTGTGTCCTGTTTTTCTTAAAGCTGTCAGTGTACAAGTGGGTATTTGAATACCAGACCTTACTGTAAAAAATAAAAA
AGGTGGTATCTAGAGCATGTAAATTGGATATAAAGTTCTGCTCTTAAAGAGTTGATCTAAGAGTATGGCTAAACATCTATATATGCAATC
TATTAAAAGAACTTAATTCGGCTATTATGTCTTGATTTGATTGCAGTTTTTTCCTAATTATAACAAATTTTTCCTCATTGGCCTGTTTTT
AATCCTGTGCCTAGAAGGAGTACAAAATGCACACTTTACAAAATTGATATTTAACACTTACCCACTCCCCTTTCCCCATCTCTTCTACCG
CTCTTGTTGATCGTGGTATCTGATCTTGACTAGATAGGCTGAAGGCACATGGTTCCCTCCAAAAACCACTATTGATACCACTACAAAAAC
AAGCCAGCAAAAAGATACTGTAGAGAGGTTGGCTTGCTTCCCTCTCTTCCTAACTGCATGTTGAAAAATAAGCCGTTATTGATCTTAAAC
ATCGGTCAGATGAGTCATACATTGGGTTATTTTTTATATACATGTATACACAAAATATTTCAAATTGAAAGCAACATCTTAATGGATTCA
AAACTATTACAAGCTGTTGTCTAAAACAGGTGAGAAAAAAATTTATAACTGTAAAAACAAATGCACATATTGATATTTAAAATGCGTAAT
TAAGAAAACCCATTGTTGTTGTGTTTTTCTTGTATACCAATAATTAAGCCACTACTGTTGGCACTGTTTGGTTTTCTATTTTAACACTGA
AGGAGTGAAAGTATTTCCTATATTTATGAATTTACTACTAAAATCTTGGCAAAAAAAGAAAAAAATTGTCTAACGTGTGTGGGTGAAAAC
TGTTAATCAAGTGTTTCTACTCCCCCCCGAAAATCCCCTGAAAGTTGGACACCAACTGTATACCCTAGGTTGCTTAAAGGGATTTCACTA
TTATATAAAGTCAATAAAAATGAAGTAGTTGTATATATGCAACATTGTGTACAGAGGGGAAATAATGAATAGTATTAAAGAAACATTCTC
GTCTTCCTTTACCTTTAATCCCCTAATACCTAGTCTACTTTTTAAATTTTCAGACTTCACTGCTTTTTGAATTCATAATTCTAATTTTCA
CATTATTGTTAATGGAAAATCATATCTAATAAAGGTTTTAGTTATTCCCATGCACAGTATGAAAATTCTCATTTGCTGAGGTTTTGTTTC
AAGAAAATGTATTGGCATGTCTTTGAGAACATGTTTTATTGTCTCCTGTGTCATATAATCCAAACTAATCTCCGTTTACAGACTTTAACT
TGAAATTAGACCTTATAATTAAACTATTTAAATAGTGTTCAAATGATAGTTTCTAATGCATCAAATATATACCTCAGTTTTCATGATTTC
CTTTAACATTATAATTTGGTATAGATCAAGAATCTTAACATGTATCAGTTTCTAGATGAGGCTGCAGGATTTTTGGAAAACTTTTTGAAT
GTATTTACAATATTCTCTTGTAATTAGCTACATAGGGACTTGTCTTTTTTTCTTTTTACATACAGCTTTTCCTACAGTTTTATTACCCTG
TAATTTTTTTTTAGTTGTAGAAGTTAATTCTGATTTTGTGTGGATTTCAGTATTTGTCTTTGTTAATGGCACATATTAGCATAAATCACT
TTTGTAAATGTAAGCTTTCTTTTTTTTTCTTGAAAAAGCCTTTCTATTTATCAGTATTAAATAAAGGAAGTTAATCTGTTTCTCTGCAGG
TAATAAAATAGTGACACACTGTATTAAGATAGTGACTGCTATACTCAACTCTGGAAGAGACTAGAGTATAGAGCATGAGTGGCAAAACCA
CAGCCCTTGGGCCATATGCTGCTATTCAGTCCCAGATGTAGCCCCTGAAGCAAGCATAAAGAAAAATGAATTAAAAATTAAATTAATATG
GAAAGTTAAAAAATGGATTACATTAGTATGACTAAACCATGTCTTTGGCAAAGATCTAACACAATGTCTTAAGTATAATAGGTAGTCTCT

>In-frame_ENST00000256190_ENST00000379719_TCGA-BR-8077-01A_SBF2_chr11_10215449_-_IPO7_chr11_9424837_length(amino acids)=1098AA_start in transcript=15_stop in transcript=3311
MKRCRCRYCRCRENAEPSRAGWAAAARAATGTRFPSAAAAAMARLADYFIVVGYDHEKPGSGEGLGKIIQRFPQKDWDDTPFPQGIELAH
KSLNFVSTLLQITMSEQLDLPVRQAGVIYLKNMITQYWPDRETAPGDISPYTIPEEDRHCIRENIVEAIIHSPELIRVQLTTCIHHIIKH
DYPSRWTAIVDKIGFYLQSDNSACWLGILLCLYQLVKNYEYKKPEERSPLVAAMQHFLPVLKDRFIQLLSDQSDQSVLIQKQIFKIFYAL
VQYTLPLELINQQNLTEWIEILKTVVNRDVPNETLQVEEDDRPELPWWKCKKWALHILARLFERYGSPGNVSKEYNEFAEVFLKAFAVGV
QQVLLKVLYQYKEKQYMAPRVLQQTLNYINQGVSHALTWKNLKPHIQGIIQDVIFPLMCYTDADEELWQEDPYEYIRMKFDVFEDFISPT
TAAQTLLFTACSKRKEVLQKTMGFCYQILTEPNADPRKKDGALHMIGSLAEILLKKKIYKDQMEYMLQNHVFPLFSSELGYMRARACWVL
HYFCEVKFKSDQNLQTALELTRRCLIDDREMPVKVEAAIALQVLISNQEKAKEYITPFIRPVMQALLHIIRETENDDLTNVIQKMICEYS
EEVTPIAVEMTQHLAMTFNQVIQTGPDEEGSDDKAVTAMGILNTIDTLLSVVEDHKEITQQLEGICLQVIGTVLQQHVLEFYEEIFSLAH
SLTCQQVSPQMWQLLPLVFEVFQQDGFDYFTDMMPLLHNYVTVDTDTLLSDTKYLEMIYSMCKKVLTGVAGEDAECHAAKLLEVIILQCK
GRGIDQCIPLFVEAALERLTREVKTSELRTMCLQVAIAALYYNPHLLLNTLENLRFPNNVEPVTNHFITQWLNDVDCFLGLHDRKMCVLG
LCALIDMEQIPQVLNQVSGQILPAFILLFNGLKRAYACHAEHENDSDDDDEAEDDDETEELGSDEDDIDEDGQEYLEILAKQAGEDGDDE
DWEEDDAEETALEGYSTIIDDEDNPVDEYQIFKAIFQTIQNRNPVWYQALTHGLNEEQRKQLQDIATLADQRRAAHESKMIEKHGGYKFS

--------------------------------------------------------------

Top

Fusion Gene PPI Analysis for SBF2-IPO7

Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in
ChiPPI page.

Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160)

Hgene

Hgene's interactors

Tgene

Tgene's interactors

- Retained PPIs in in-frame fusion.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Still interaction with

- Lost PPIs in in-frame fusion.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Interaction lost with

- Retained PPIs, but lost function due to frame-shift fusion.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Interaction lost with

Top

Related Drugs for SBF2-IPO7

Drugs targeting genes involved in this fusion gene.
(DrugBank Version 5.1.8 2021-05-08)

Partner

Gene

UniProtAcc

DrugBank ID

Drug name

Drug activity

Drug type

Drug status

Top

Related Diseases for SBF2-IPO7

Diseases associated with fusion partners.
(DisGeNet 4.0)

Partner	Gene	Disease ID	Disease name	# pubmeds	Source
Hgene	SBF2	C1858278	Charcot-Marie-Tooth disease, Type 4B2	2	CTD_human;GENOMICS_ENGLAND
Tgene	IPO7	C0019693	HIV Infections	1	CTD_human
Tgene	IPO7	C4505456	HIV Coinfection	1	CTD_human